Pharmaceutical Control of the
Human Microbiome

Management

Ward Peterson, PhD
Co-founder, President and CEO

Dr. Peterson has 16 years experience in pharma R&D—drug discovery to Phase 3 studies involving multiple targets and therapeutic areas. His previous employment was with Regeneron Pharmaceuticals and Inspire Pharmaceuticals (Research Scientist to Senior VP).

Matthew Redinbo, PhD
Co-founder and Chief Scientific Officer
Dr. Redinbo is the inventor of Symberix's technology licensed from University of North Carolina, Chapel Hill. He has 25 years of experience in biochemistry, structural and chemical biology. Dr. Redinbo is the Kenan Distinguished Professor of Chemistry, Biochemistry, Microbiology and Genomics at UNC, Chapel Hill.
Gregory J. Mossinghoff
Chief Business Officer

Mr. Mossinghoff has over 25 years of domestic and international bio-pharmaceutical industry experience. His responsibilities have included general and financial management, corporate development and licensing, strategic and product planning, market research, opportunity modeling and financial analysis. Starting with a 10-year big-pharma foundation at Roche and Glaxo, he has subsequent experience as a senior executive in numerous emerging bio-pharmaceutical companies in various roles such as Board Member, President, CEO, CBO, CFO, Principal Financial Officer and Co-Founder. He has a strong understanding of business planning, technology valuation, partnering, corporate governance, intellectual property, public/private capital markets and fund-raising.  Formulating and communicating to investors the value proposition of key assets, he has co-led multiple venture financing rounds and two successful biotech IPOs: G1 Therapeutics, with a current market capitalization of over $1.5b; and Inspire Pharmaceuticals, which was subsequently acquired by Merck & Co. In total he has participated in raising more than $450m in public and private equity capital and has negotiated and closed more than twenty important licensing/partnership agreements. He currently acts as an executive advisor to several emerging life-science companies. Mr. Mossinghoff has a BA in Economics from the University of Virginia and an MBA in Financial Management and Analysis from George Mason University..